This inventor holds 2 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Novartis Ag. Active years: 2023-2026.
Company Filing History:
Years Active: 2023-2026
Title: Klaus-Peter Moll: Innovator in Pharmaceutical Formulations
Introduction
Klaus-Peter Moll is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of drug formulations. With a total of 2 patents to his name, Moll's work focuses on innovative solutions for treating complex medical conditions.
Latest Patents
Moll's latest patents include a modified release formulation for (-)-(3AR,4S,7AR)-4-hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester. This drug product is designed to aid patients suffering from Parkinson's disease and L-dopa induced dyskinesia. Additionally, he has developed a method for preparing granules, which involves creating a slurry of solid active pharmaceutical ingredient (API) powder particles mixed with a dry base powder to produce granules that enhance drug delivery.
Career Highlights
Klaus-Peter Moll is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative drug formulations that improve patient outcomes. His expertise in pharmaceutical sciences has positioned him as a key player in the industry.
Collaborations
Moll has collaborated with several professionals in his field, including Arnaud Grandeury and Bruno Galli. These collaborations have contributed to the advancement of his research and the successful development of his patented formulations.
Conclusion
Klaus-Peter Moll's contributions to pharmaceutical innovations demonstrate his commitment to improving healthcare solutions. His patents reflect a deep understanding of drug formulation processes that can significantly benefit patients.